Former Pfizer Executive Dr. Andreas Penk Joins Bioneex Advisory Board

Tue Oct 11 2022 11:04:34 GMT+0000 (Coordinated Universal Time)

Bioneex expands senior advisory team to support expansion into global oncology space and addition of Chinese biopharma innovation to its exchange platform

NEW YORK, Oct. 11, 2022 /PRNewswire-PRWeb/ -- BioNeex (, the biopharma industry’s first research and development (R&D) open exchange platform, announced today former Pfizer executive Dr. Andreas Penk has joined its Advisory Board. The growing company has helped more than 160 preclinical and early clinical-stage biotech companies identify out-licensing and co-development partnership opportunities and venture capital investments for their drug candidates in the pipeline.

Dr. Andreas Penk is a trained physician with 26 years of experience working on behalf of Pfizer throughout the world. In 2021, he retired as the President of Pfizer Biopharmaceuticals Group China. Dr. Penk also served as Pfizer’s Regional President of Oncology International Developed Markets during his career. He brings extensive hands-on experience working within the biopharma industry across China and around the world to his leadership position with Bioneex.

“We are proud to welcome Dr. Andreas Penk to Bioneex’s Board of Advisors, and look forward to the expertise and global connections he brings through his successful, long-term career in the industry,” said Dr. Smbat Rafayelyan, Founder & CEO of Bioneex. “Under the direction of his skilled leadership and advice, Bioneex aims to bring Chinese biopharma innovation onto its exchange platform and expand into the global Oncology space, helping development-stage biotech companies to connect globally with biopharma companies and venture capital firms for new R&D licensing, co-development partnerships, and investment opportunities worldwide.”

Showcasing the ongoing success of Bioneex’s innovative exchange and global vision, two life sciences industry leaders and Bioneex clients are now investors in the company. Ten of the twenty largest biopharmaceutical companies use the Bioneex platform to strengthen their R&D pipelines.

“Bioneex’s cutting-edge technology solution is pushing the future of the biopharma industry forward, as it connects preclinical and early clinical-stage biotech companies with the biopharma partners and venture investors needed to reach the late-stage clinical development and introduce novel medicines to patients,” said Dr. Andreas Penk. “After joining the Bioneex Advisory Board, I look forward to supporting the addition of even more biopharma innovators to the platform, especially from the Oncology space, including those coming throughout Asia.”

A two-sided marketplace, the Bioneex exchange platform delivers global biopharma industry partners and venture capital firms the most complete, accurate, and up-to-date drug candidates data available, posted directly by drug candidate developers. The exchange is highly focused on novel drug candidates – new molecular entities (NMEs) that are first-in-class, best-in-class. Bioneex is improving how biopharmaceutical companies and venture capital firms identify drug candidates for in-licensing and investment opportunities, backed by proprietary real-time data on industry trends and analysis.

Earlier this year, BioNeex announced a partnership with ALSA Ventures, a life science venture capital investor focused on early-stage novel therapeutics, demonstrating how BioNeex provides biotech firms a new way to drug candidate out-licensing and acquiring investment.

About Bioneex

Bioneex is the first R&D open exchange platform in the biopharma industry, a two-sided marketplace that directly connects biotech, biopharmaceutical companies, and venture capital firms to facilitate licensing and co-development partnership deals for preclinical and clinical-stage drug candidates, as well as investments. The marketplace enables potential licensing and co-development partners and investors to access the most complete, accurate, and up-to-date drug candidate data, posted directly by drug candidate developers, and to contact them directly with one click. For more information, please visit:

Source:  PRWeb

Schedule a call or send us a message
Schedule Call
Contact us